ALK and non-small cell lung carcinoma: The latter two scenarios are fairly common in the setting of oncogene-addicted NSCLC (those patients with ALK rearrangements or EGFR mutations) and are due predominantly to acquired resistance to treatment with TKIs in progressing/resistant tumor clonogens (38).